Quarterly ResultAug 5, 2026, 05:29 PM
Zevra Q2 Revenue Up 53% to $39.7M; Net Income $8.8M
AI Summary
Zevra Therapeutics reported a 53% increase in Q2 2026 net revenue to $39.66 million. However, net income decreased to $8.75 million from $74.71 million in Q2 2025, primarily due to a large gain on a PRV sale in the prior year. For the six months ended June 30, 2026, the company recognized a $43.31 million gain from the sale of its SDX portfolio to Commave Therapeutics. Additionally, the European Medicines Agency's CHMP adopted a negative opinion regarding the Marketing Authorization Application for arimoclomol in July 2026, for which the company has requested a re-examination.
Key Highlights
- Q2 2026 net revenue increased 53% to $39.66 million from $25.88 million in Q2 2025.
- Q2 2026 net income was $8.75 million, down from $74.71 million in Q2 2025.
- Q2 2026 basic EPS was $0.14, compared to $1.24 in Q2 2025.
- EMA's CHMP adopted a negative opinion on arimoclomol MAA in July 2026; re-examination requested.
- Sold SDX portfolio to Commave for $50.0 million, recognizing a $43.31 million gain in H1 2026.
- Cash and cash equivalents increased to $145.32 million as of June 30, 2026, from $62.41 million at Dec 31, 2025.
- Net cash provided by operating activities was $23.17 million for H1 2026, compared to $(11.82) million used in H1 2025.
- Repaid $60.09 million in long-term debt during H1 2026.
Price Impact
More from ZVRA